Focused On-demand Library for LIM domain kinase 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P53667

UPID:
LIMK1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P53667; B7Z6I8; D3DXF4; D3DXF5; O15283; Q15820; Q15821; Q75MU3; Q9Y5Q1

BACKGROUND:
LIM domain kinase 1, a serine/threonine-protein kinase, plays a critical role in actin filament dynamics, acting downstream of Rho GTPase signal pathways. It is activated by kinases such as ROCK1 and PAK1, leading to the phosphorylation of actin depolymerizing factors, including cofilin, thereby stabilizing the actin cytoskeleton. This process is essential for various biological functions like cell motility and differentiation. LIMK1 also affects microtubule dynamics by phosphorylating TPPP.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of LIM domain kinase 1 offers a pathway to identifying novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.